PCSK9 inhibitors
What is the primary action of PCSK9 inhibitors (e.g., Praluent or Repatha) in cholesterol control? They increase the breakdown of LDL in the bloodstream. They bind to LDL receptors, enhancing their degradation. They reduce the absorption of cholesterol in the gut. They block PCSK9, allowing more LDL receptors on cell surfaces. […]